During the last session, Carisma Therapeutics Inc (NASDAQ:CARM)’s traded shares were 0.49 million, with the beta value of the company hitting 1.59. At the end of the trading day, the stock’s price was $0.53, reflecting an intraday gain of 20.00% or $0.09. The 52-week high for the CARM share is $2.94, that puts it down -454.72 from that peak though still a striking 28.3% gain since the share price plummeted to a 52-week low of $0.38. The company’s market capitalization is $22.04M, and the average intraday trading volume over the past 10 days was 0.32 million shares, and the average trade volume was 235.85K shares over the past three months.
Carisma Therapeutics Inc (CARM) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.60. CARM has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it.
Carisma Therapeutics Inc (NASDAQ:CARM) trade information
Carisma Therapeutics Inc (CARM) registered a 20.00% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 20.00% in intraday trading to $0.53, hitting a weekly high. The stock’s 5-day price performance is 19.48%, and it has moved by -37.44% in 30 days. Based on these gigs, the overall price performance for the year is -81.07%. The short interest in Carisma Therapeutics Inc (NASDAQ:CARM) is 0.57 million shares and it means that shorts have 2.16 day(s) to cover.
The consensus price target of analysts on Wall Street is $6, which implies an increase of 91.17% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6 and $6 respectively. As a result, CARM is trading at a discount of -1032.08% off the target high and -1032.08% off the low.
Carisma Therapeutics Inc (CARM) estimates and forecasts
Statistics show that Carisma Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Carisma Therapeutics Inc (CARM) shares have gone down -54.08% during the last six months, with a year-to-date growth rate more than the industry average at 49.03% against 16.60.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 24.98%. While earnings are projected to return 53.13% in 2025.
CARM Dividends
Carisma Therapeutics Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Carisma Therapeutics Inc (NASDAQ:CARM)’s Major holders
Carisma Therapeutics Inc insiders own 27.40% of total outstanding shares while institutional holders control 31.47%, with the float percentage being 43.34%.
